PaxMedica Submits Clinical Trial Request In Autism Spectrum Disorder
Portfolio Pulse from Happy Mohamed
PaxMedica has submitted a request to South Africa's SAHPRA for approval to conduct a double-blind, placebo-controlled study, PAX-ASD-101, for the treatment of Autism Spectrum Disorder (ASD). The trial aims to enroll 30 subjects aged 4 to 18 and is expected to begin in Q4 2023. PaxMedica is also preparing additional submissions for planned PAX-101 trials with other regulatory authorities outside of South Africa in 2023.
June 14, 2023 | 12:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
PaxMedica's submission of PAX-ASD-101 trial request to SAHPRA may lead to potential approval and initiation of the trial in Q4 2023, which could positively impact the company's stock.
The submission of the PAX-ASD-101 trial request to SAHPRA indicates progress in PaxMedica's efforts to develop a treatment for Autism Spectrum Disorder. If approved, the trial could begin in Q4 2023, which may lead to positive results and further advancements in the company's ASD program. This progress could positively impact PaxMedica's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100